Oncology Posters and Publications

Oncology Posters and Publications

Oncology Posters and Publications

Monogram Biosciences has presented data to demonstrate our portfolio of VeraTag® assays at recent clinical and scientific meetings. The publications and abstracts support the clinical utility and flexibility of VeraTag technology, our proprietary, novel, proximity-based platform that quantifies functional protein-protein interactions and protein expression.

Publication

Yardley DA, Kaufman PA, Huang, et al. Quantitative measurement of HER2 expression in breast cancers: comparison with “real world” routine HER2 testing in a multi-center Collaborative Biomarker Study and correlation with overall survival. Breast Cancer Research. 2015;17:41. DOI 10.1186/s13058-015-0543-x 

Publication

Duchnowska R, Biernat W, Szostakiewicz B, et al. Correlation between quantitative HER2 protein expression and risk of brain metastasis in HER2-positive advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist. 2012;17(1):26-35. doi: 10.1634/theoncologist.2011-0212. Epub 2012 Jan 10.

Publication

DeFazio-Eli L, Strommen K, Dao-Pick T, et al. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Research. 2011;13:R44.

Publication

Ghosh M, Narasanna A, Wang SE, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Research. 2011;71(5):1871-1872.

Publication

Bates M, Sperinde J, Köstler WJ, et al. Identification of a sub-population of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Ann Oncol. 201;22(9):2014-2020.

Publication

Joensuu H, Sperinde J, Leinonen M, et al. Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol. 2011;22(9):2007-2013.

Publication

Mukherjee A, Badal Y, Nguyen XT, et al. Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins. PLOS One. 2011;6(1):e16443.

Publication

Dua R, Zhang J, Penuel E. Detetion of hepatocyte growth factor (HGF) ligand-C-met receptor activation in formalin-fixed, paraffin-embedded specimens by a novel proximity assay. PLOS One. 201;6(1):e15932.

Publication

Lipton A, Köfstler W, Leitzel K, et al. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer. 2010;116:5168-5178.

Publication

Sperinde J, Jin X, Banerjee J, et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clinical Cancer Research. 2010;16(16):4226-4235.

Publication

Dua R, Zhang J, Nhonthachit P, et al. EGFR over-expression and activation in high HER2, ER negative breast cancer cell lines induces trastuzumab resistance. Breast Cancer Res Treat. 2010;122(3):685-697.

Publication

Larson JS, Goodman LJ, Tan Y, et al. Analytical validation of a highly sensitive, accurate, and reproducible assay (HERmark®) for the measurement of HER2 total protein and HER2 Homodimers in FFPE breast cancer tumor specimens. Pathology Research International. 2010 Jun 28;2010:814176. doi: 10.4061/2010/814176.

Publication

Jain A, Penuel E, Mink S, et al. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Research. 2010;70(5):1989-1999.

Publication

 Mamluk R, Carvajal IM, Morse BA, et al. Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs. 2010; 2(2):199-208.

Publication

Toi M, Sperinde J, Huang W, et al. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. BMC Cancer. 2011; 10:56.

Publication

Shi Y, Huang W, Tan Y, et al. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol. 2009;18(1):11-21.

Publication

Desmedt C, Sperinde J, Piette F, et al. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol. 2009;18:22-9.

Poster

Quantitative HER3 protein expression and PIK3CA mutation status in matched samples from primary and metastatic breast cancer tissues and correlation with time to recurrence J Sperinde, J Lara, R Michaelson, X Sun, P Conte, V Guarneri, E Barbieri, SM Ali, K Leitzel, J Weidler, Y Lie, J Cook, M Haddad, A Paquet, J Winslow, J Howitt, L Hurley, M Eisenberg, C Petropoulos, W Huang and A Lipton, SABCS 2012.

Poster

Subclassification of squamous cell carcinomas of the head and neck based on HER/ErbB and c-MET receptor protein expression and activation profiles Jerry Wallweber, Youssouf Badal, Brian Twomey, Tam Dang, Jolly Bose Trang Dao-Pick, Jianhuan Zhang, Dave Stathas, Rajiv Dua, Agnes Paquet. AACR, 2011.

Poster

Correlation of quantitative p95HER2 and total HER2 levels with clinical outcomes in a combined analysis of two cohorts of trastuzumab-treated metastatic breast cancer patients R Duchnowska, J Sperinde, K Leitzel, B Szostakiewicz, A Paquet, SM Ali, T Jankowski, M Haddad, E Fuchs, B Arlukowicz-Czartoryska, J Winslow, C F Singer, PJ Wysocki ,Y Lie, R Horvat, M Foszczynska-Kloda, C Petropoulos, B. Radecka, MM Litwiniuk, S Debska, J Weidler, W Huang, W Biernat, WJ Köstler, J Jassem, A Lipton, SABCS 2012.

Poster

Multiple Subtypes of HER-2/neu-positive Metastatic Breast Cancer Allan Lipton, Kim Leitzel, Wolfgang Koestler, Eva-Maria Fuchs, Christian F Singer, Suhail M Ali, Weidong Huang, Jeff Sperinde, Laurie Goodman, Xueguang Jin, Jayee Banerjee, Jennifer Weston, Ali Mukherjee, Jeff Larson, Jodi Weidler, Agnes Paquet, Steve Williams, John Winslow, Gordon Parry, Michael Bates. SABCS, 2009.

Poster

Quantitative measurement of HER2 expression in breast cancers: comparison with “real world” HER2 testing in a multi-center Collaborative Biomarker Study (CBS) and correlation with clinicopathological features Denise A. Yardley MD,, Peter A. Kaufman MD, John W. Adams MD, Lea Krekow MD, Michael Savin MD, William E Lawler MD, Stephen Zrada MD, Alexander Starr MD, Harvey Einhorn MD, Lee S. Schwartzberg MD, Weidong Huang MD, Jodi Weidler PharmD, Yolanda Lie, Agnes Paquet MS, Mojgan Haddad PhD, Jeff Sperinde PhD, Steve Anderson PhD, Marlon Brigino, Linda Bosserman MD, SABCS 2012.

Poster

Correlation of quantitative p95HER2, HER3, and HER2 protein expression with pathologic complete response (pCR) in HER2-positive breast cancer patients treated with neoadjuvant (NEO) trastuzumab containing therapy JC Villasboas, J Hurley, JM Weidler, A Paquet, C Gomez-Fernandez, M Cioffi, J Sperinde, A Chenna, M Haddad, Y Lie, J Winslow, W Huang, C Petropoulos, M Pegram, ASCO 2012.

Poster

Quantitative HER2 levels and steroid receptor expression in primary breast cancers and in matched brain metastases W Biernat, R Duchnowska, T Trojanowski, T Mandat, A Kowalczyk, B Czartoryska-Arlukowicz, B Radecka, B Jarosz, R Staszkiewicz, E Kalinka-Warzocha, M Chudzik, J Sperinde, M Haddad, A Paquet, Y Lie, J Winslow, JM Weidler, W Huang, C Petropoulos, J Jassem, ASCO 2012.

Publication

Huang W, Reinholz M, Weidler J, et al. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity based assay. Am J Clin Pathol. 2010;134:303-311.